{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:51:38Z","timestamp":1791154298559,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068632"],"award-info":[{"award-number":["UM1AI068632"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068616"],"award-info":[{"award-number":["UM1AI068616"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI106716"],"award-info":[{"award-number":["UM1AI106716"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["HHSN275201800001I"],"award-info":[{"award-number":["HHSN275201800001I"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"DOI":"10.1007\/s40262-026-01690-w","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:48:43Z","timestamp":1791035323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics of Efavirenz in Pregnancy and Postpartum with and Without First-line Tuberculosis Drugs: Results from\u00a0IMPAACT P1026s"],"prefix":"10.1007","clinical-trial-number":[{"clinical-trial-number":"nct00042289","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2679-901X","authenticated-orcid":false,"given":"Marije","family":"Van Schalkwyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2371-8850","authenticated-orcid":false,"given":"Jiajia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3836-3432","authenticated-orcid":false,"given":"Adrie","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1815-5150","authenticated-orcid":false,"given":"Eric","family":"Decloedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8888-1436","authenticated-orcid":false,"given":"Gerhard B.","family":"Theron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2559-6034","authenticated-orcid":false,"given":"Mark F.","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-0974","authenticated-orcid":false,"given":"Tim R.","family":"Cressey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8923-2005","authenticated-orcid":false,"given":"Deo","family":"Wabwire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2412-4790","authenticated-orcid":false,"given":"Chelsea","family":"Stotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7589-3306","authenticated-orcid":false,"given":"Kevin","family":"Knowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3839-9478","authenticated-orcid":false,"given":"Renee","family":"Browning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kittipong","family":"Rungruengthanakit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9070-8699","authenticated-orcid":false,"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1630-0505","authenticated-orcid":false,"given":"Edmund V.","family":"Capparelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice M.","family":"Stek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3600-1502","authenticated-orcid":false,"given":"Mark","family":"Mirochnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6051-7745","authenticated-orcid":false,"given":"David E.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8569-2293","authenticated-orcid":false,"given":"Brookie M.","family":"Best","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0070-9840","authenticated-orcid":false,"given":"Ahizechukwu C.","family":"Eke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the IMPAACT P1026s Protocol Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Benns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Burchett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nantasak","family":"Chotivanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Garcia-Prats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Hesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzague","family":"Jourdain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regis","family":"Kreitchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikhulile","family":"Moyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Frenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Reding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"issue":"3","key":"1690_CR1","doi-asserted-by":"publisher","first-page":"e337","DOI":"10.1016\/S2214-109X(25)00431-0","volume":"14","author":"N Mafirakureva","year":"2026","unstructured":"Mafirakureva N, Cartledge A, Bradshaw I, Bekker A, Salazar-Austin N, Meehan SA, et al. Global estimates of tuberculosis incidence during pregnancy and postpartum: a rapid review and modelling analysis. Lancet Glob Health. 2026;14(3):e337\u201346.","journal-title":"Lancet Glob Health"},{"key":"1690_CR2","unstructured":"World Health Organization. Trends in maternal mortality estimates 2000 to 2023: estimates by WHO, UNICEF, UNFPA, World Bank Group and UNDESA\/Population Division. Geneva, Switzerland: WHO. 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240108462. Accessed 30 Jun 2026."},{"issue":"2","key":"1690_CR3","first-page":"11","volume":"4","author":"SA Holtz","year":"2015","unstructured":"Holtz SA, Thetard R, Konopka SN, Albertini J, Amzel A, Fogg KP. A Systematic Review of Interventions to Reduce Maternal Mortality among HIV-Infected Pregnant and Postpartum Women. Int J MCH AIDS. 2015;4(2):11\u201324.","journal-title":"Int J MCH AIDS."},{"key":"1690_CR4","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva, Switzerland: WHO. 2013. https:\/\/www.who.int\/publications\/i\/item\/9789241505727. Accessed 30 Jun 2026."},{"issue":"2","key":"1690_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/infdis\/jiu429","volume":"211","author":"KE Dooley","year":"2015","unstructured":"Dooley KE, Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, et al. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. J Infect Dis. 2015;211(2):197\u2013205.","journal-title":"J Infect Dis"},{"issue":"7","key":"1690_CR6","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3018(23)00081-4","volume":"10","author":"R Griesel","year":"2023","unstructured":"Griesel R, Zhao Y, Simmons B, Omar Z, Wiesner L, Keene CM, et al. Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial. Lancet HIV. 2023;10(7):e433\u201341.","journal-title":"Lancet HIV"},{"issue":"1","key":"1690_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1124\/jpet.103.049601","volume":"306","author":"BA Ward","year":"2003","unstructured":"Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306(1):287\u2013300.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"1690_CR8","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1093\/jac\/dku110","volume":"69","author":"DW Haas","year":"2014","unstructured":"Haas DW, Kwara A, Richardson DM, Baker P, Papageorgiou I, Acosta EP, et al. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. J Antimicrob Chemother. 2014;69(8):2175\u201382.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"1690_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/jac\/dkn029","volume":"61","author":"C Wyen","year":"2008","unstructured":"Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008;61(4):914\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"1690_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/135965350901400502","volume":"14","author":"K Cohen","year":"2009","unstructured":"Cohen K, Grant A, Dandara C, McIlleron H, Pemba L, Fielding K, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther. 2009;14(5):687\u201395.","journal-title":"Antivir Ther"},{"issue":"6","key":"1690_CR11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00228-023-03489-1","volume":"79","author":"A Alshabi","year":"2023","unstructured":"Alshabi A, Shaik IH, Zhao Y, Pillai VC, Caritis S, Venkataramanan R. A cocktail probe approach to evaluate the effect of hormones on the expression and activity of CYP enzymes in human hepatocytes with conditions simulating late stage of pregnancy. Eur J Clin Pharmacol. 2023;79(6):815\u201327.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1690_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.ajog.2004.08.030","volume":"192","author":"TS Tracy","year":"2005","unstructured":"Tracy TS, Venkataramanan R, Glover DD, Caritis SN, National Institute for Child H, Human Development Network of Maternal-Fetal-Medicine U. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol. 2005;192(2):633\u20139.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"1690_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/cpt.43","volume":"97","author":"A Olagunju","year":"2015","unstructured":"Olagunju A, Bolaji O, Amara A, Else L, Okafor O, Adejuyigbe E, et al. Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics. Clin Pharmacol Ther. 2015;97(3):298\u2013306.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1690_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","volume":"15","author":"C Marzolini","year":"2001","unstructured":"Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15(1):71\u20135.","journal-title":"AIDS"},{"key":"1690_CR15","doi-asserted-by":"crossref","unstructured":"Kreitchmann R, Schalkwijk S, Best B, Wang J, Colbers A, Stek A, et al. Efavirenz pharmacokinetics during pregnancy and infant washout. Antivir Ther. 2019 2019\u201302\u201301;24(2):95\u2013103.","DOI":"10.3851\/IMP3283"},{"issue":"3","key":"1690_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/QAI.0b013e31823ff052","volume":"59","author":"TR Cressey","year":"2012","unstructured":"Cressey TR, Stek A, Capparelli E, Bowonwatanuwong C, Prommas S, Sirivatanapa P, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr. 2012;59(3):245\u201352.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"1690_CR17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/cid\/ciy161","volume":"67","author":"M Lamorde","year":"2018","unstructured":"Lamorde M, Wang X, Neary M, Bisdomini E, Nakalema S, Byakika-Kibwika P, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of efavirenz 400 mg once daily during pregnancy and post-partum. Clin Infect Dis. 2018;67(5):785\u201390.","journal-title":"Clin Infect Dis"},{"key":"1690_CR18","unstructured":"The International Maternal Pediatric Adolescent AIDS Clinical Trials Network. IMPAACT P1026s - Pharmacokinetic Properties of Antiretroviral Therapy During Pregnancy. 2013. https:\/\/www.impaactnetwork.org\/studies\/p1026s. Accessed 30 Jun 2026."},{"issue":"9","key":"1690_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00052-25","volume":"69","author":"M Van Schalkwyk","year":"2025","unstructured":"Van Schalkwyk M, Bekker A, Decloedt E, Wang J, Theron GB, Cotton MF, et al. Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study. Antimicrob Agents Chemother. 2025;69(9):e00052-25.","journal-title":"Antimicrob Agents Chemother"},{"key":"1690_CR20","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-susceptible tuberculosis treatment. Geneva, Switzerland: WHO. 2022. https:\/\/www.who.int\/publications\/i\/item\/9789240048126. Accessed 30 Jun 2026."},{"issue":"12","key":"1690_CR21","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1093\/cid\/civ155","volume":"60","author":"AF Luetkemeyer","year":"2015","unstructured":"Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, et al. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis. 2015;60(12):1860\u20133.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1690_CR22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/bcp.12590","volume":"80","author":"PZ Sinxadi","year":"2015","unstructured":"Sinxadi PZ, Leger PD, McIlleron HM, Smith PJ, Dave JA, Levitt NS, et al. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa. Br J Clin Pharmacol. 2015;80(1):146\u201356.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1690_CR23","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.4102\/sajhivmed.v26i1.1661","volume":"26","author":"J Taylor","year":"2025","unstructured":"Taylor J, Maartens G, Sokhela S, Chandiwana N, Akpomiemie G, Venter F, et al. Pharmacokinetics, pharmacogenetics, and toxicity of co-administered efavirenz and isoniazid. Southern Afr J HIV Med. 2025;26(1):1661.","journal-title":"Southern Afr J HIV Med."},{"issue":"16","key":"1690_CR24","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1097\/QAD.0b013e3283319908","volume":"23","author":"A Kwara","year":"2009","unstructured":"Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS. 2009;23(16):2101\u20136.","journal-title":"AIDS"},{"issue":"12","key":"1690_CR25","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1097\/FPC.0b013e32835a450b","volume":"22","author":"ER Holzinger","year":"2012","unstructured":"Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics. 2012;22(12):858\u201367.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"1690_CR26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1006\/bbrc.2001.4990","volume":"284","author":"M Pitarque","year":"2001","unstructured":"Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun. 2001;284(2):455\u201360.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1690_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/pds.570","volume":"10","author":"HI Seifart","year":"2001","unstructured":"Seifart HI, Parkin DP, Botha FJH, Donald PR, Van Der Walt BJ. Population screening for isoniazid acetylator phenotype. Pharmacoepidemiol Drug Saf. 2001;10(2):127\u201334.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"1690_CR28","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00737-23","volume":"67","author":"M Van Schalkwyk","year":"2023","unstructured":"Van Schalkwyk M, Bekker A, Decloedt E, Wang J, Theron GB, Cotton MF, et al. Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s. Antimicrob Agents Chemother. 2023;67(11):e00737-23.","journal-title":"Antimicrob Agents Chemother"},{"key":"1690_CR29","unstructured":"Sustiva package insert. Princeton: Bristol-Myers Squibb Company. 2019. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/drugs\/documents\/269\/FDA_Label%26_Capsule_%28gelatin_coated%29%2C_tablet_%28film_coated%29.pdf. Accessed 30 Jun 2026."},{"issue":"3","key":"1690_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/sper.2001.24565","volume":"25","author":"MC Frederiksen","year":"2001","unstructured":"Frederiksen MC. Physiologic changes in pregnancy and their effect on drug disposition. Semin Perinatol. 2001;25(3):120\u20133.","journal-title":"Semin Perinatol"},{"issue":"5","key":"1690_CR31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1515\/jbcpp-2021-0312","volume":"33","author":"AC Eke","year":"2022","unstructured":"Eke AC. An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomics. J Basic Clin Physiol Pharmacol. 2022;33(5):581\u201398.","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"2","key":"1690_CR32","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1128\/AAC.02023-12","volume":"57","author":"W Manosuthi","year":"2013","unstructured":"Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, et al. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV\/tuberculosis-coinfected patients. Antimicrob Agents Chemother. 2013;57(2):1019\u201324.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1690_CR33","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1111\/bcp.13600","volume":"84","author":"D Atwine","year":"2018","unstructured":"Atwine D, Bonnet M, Taburet AM. Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: a systematic review. Br J Clin Pharmacol. 2018;84(8):1641\u201358.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1690_CR34","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/cpt.156","volume":"98","author":"L Dickinson","year":"2015","unstructured":"Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, et al. Pharmacokinetic and pharmacodynamic comparison of once-daily efavirenz (400 mg vs. 600 mg) in treatment-naive HIV-infected patients: results of the ENCORE1 study. Clin Pharmacol Ther. 2015;98(4):406\u201316.","journal-title":"Clin Pharmacol Ther"},{"key":"1690_CR35","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva, Switzerland: WHO. 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240031593. Accessed 30 Jun 2026."},{"issue":"3","key":"1690_CR36","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/cid\/civ317","volume":"61","author":"A Olagunju","year":"2015","unstructured":"Olagunju A, Bolaji O, Amara A, Waitt C, Else L, Adejuyigbe E, et al. Breast milk pharmacokinetics of efavirenz and breastfed infants\u2019 exposure in genetically defined subgroups of mother-infant pairs: an observational study. Clin Infect Dis. 2015;61(3):453\u201363.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1690_CR37","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/QAI.0000000000002859","volume":"89","author":"LL Abuogi","year":"2022","unstructured":"Abuogi LL, Castillo-Mancilla J, Hampanda K, Owuor K, Odwar T, Onono M, et al. Tenofovir diphosphate in dried blood spots in pregnant and postpartum women with HIV in Kenya: a novel approach to measuring peripartum adherence. J Acquir Immune Defic Syndr. 2022;89(3):310\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"1690_CR38","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1080\/09540121.2018.1503637","volume":"30","author":"K Brittain","year":"2018","unstructured":"Brittain K, Remien RH, Mellins CA, Phillips TK, Zerbe A, Abrams EJ, et al. Determinants of suboptimal adherence and elevated HIV viral load in pregnant women already on antiretroviral therapy when entering antenatal care in Cape Town, South Africa. AIDS Care. 2018;30(12):1517\u201323.","journal-title":"AIDS Care"},{"issue":"2","key":"1690_CR39","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/QAI.0b013e31828bb721","volume":"63","author":"M Van Schalkwyk","year":"2013","unstructured":"Van Schalkwyk M, Andersson MI, Zeier MD, La Grange M, Taljaard JJ, Theron GB. The impact of revised PMTCT guidelines: a view from a public sector ARV clinic in Cape Town, South Africa. J Acquir Immune Defic Syndr. 2013;63(2):234\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"1690_CR40","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/jinfdis\/jiq064","volume":"203","author":"A Gupta","year":"2011","unstructured":"Gupta A, Bhosale R, Kinikar A, Gupte N, Bharadwaj R, Kagal A, et al. Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus. J Infect Dis. 2011;203(3):358\u201363.","journal-title":"J Infect Dis"},{"issue":"1","key":"1690_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-11817-2","volume":"25","author":"A Jasper","year":"2025","unstructured":"Jasper A, Fourie W, Chetty S. The safety of cabotegravir in pregnancy: a systematic review and meta-analysis. BMC Infect Dis. 2025;25(1):1550.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1690_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-025-00746-z","volume":"22","author":"T Crocker-Buque","year":"2025","unstructured":"Crocker-Buque T, Moso MA, Denholm JT, Singh KP. An update on the clinical management of HIV and tuberculosis co-infection in pregnancy: TB preventative therapy, long-acting ARVs, and bedaquiline-based regimens. Curr HIV\/AIDS Rep. 2025;22(1):37.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"9","key":"1690_CR43","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1111\/bcp.16154","volume":"90","author":"A Steulet","year":"2024","unstructured":"Steulet A, Obura B, Waitt C, Laker E, Nicol MR, Cresswell FV. Clinical pharmacology considerations and drug-drug interactions with long-acting cabotegravir and rilpivirine relevant to sub-Saharan Africa. Br J Clin Pharmacol. 2024;90(9):2079\u201391.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1690_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/17425255.2024.2415295","volume":"21","author":"C Marzolini","year":"2025","unstructured":"Marzolini C, Gibbons S, Seddon D, Khoo S. Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir. Expert Opin Drug Metab Toxicol. 2025;21(2):161\u201372.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"1690_CR45","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/pharmaceutics17070913","volume":"17","author":"N Briceno-Patino","year":"2025","unstructured":"Briceno-Patino N, Prieto MC, Manrique P, Calderon-Ospina CA, Gomez L. Pharmacokinetic adaptations in pregnancy: implications for optimizing antiretroviral therapy in HIV-positive women. Pharmaceutics. 2025;17(7). https:\/\/doi.org\/10.3390\/pharmaceutics17070913.","journal-title":"Pharmaceutics"},{"key":"1690_CR46","doi-asserted-by":"publisher","first-page":"9231835","DOI":"10.1155\/2018\/9231835","volume":"2018","author":"MS Xavier","year":"2018","unstructured":"Xavier MS, Trajman A, Schmaltz CAS, Sant\u2019anna FM, Maia IR, Hadad DJ, et al. Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial. Biomed Res Int. 2018;2018:9231835.","journal-title":"Biomed Res Int"},{"issue":"10","key":"1690_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae585","volume":"11","author":"M Berton","year":"2024","unstructured":"Berton M, Stader F, Bettonte S, Battegay M, Marzolini C. Ideal time to conduct a pharmacokinetic investigation after delivery to fully capture the effect of pregnancy on drug exposure. Open Forum Infect Dis. 2024;11(10):ofae585.","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"1690_CR48","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.3390\/pharmaceutics15102455","volume":"15","author":"P Coppola","year":"2023","unstructured":"Coppola P, Butler A, Cole S, Kerwash E. Total and free blood and plasma concentration changes in pregnancy for medicines highly bound to plasma proteins: application of physiologically based pharmacokinetic modelling to understand the impact on efficacy. Pharmaceutics. 2023;15(10):2455. https:\/\/doi.org\/10.3390\/pharmaceutics15102455.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1690_CR49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cpt.2048","volume":"110","author":"AC Eke","year":"2021","unstructured":"Eke AC, Olagunju A, Momper J, Penazzato M, Abrams EJ, Best BM, et al. Optimizing pharmacology studies in pregnant and lactating women using lessons from HIV: a consensus statement. Clin Pharmacol Ther. 2021;110(1):36\u201348.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01690-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01690-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01690-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:01:29Z","timestamp":1791151289000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01690-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":49,"alternative-id":["1690"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01690-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study cannot be made publicly available because of the ethical restrictions in the study\u2019s informed consent documents and in the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network\u2019s approved human subjects protection plan; public availability may compromise participant confidentiality. However, data are available to all interested researchers upon reasonable request to the IMPAACT Statistical and Data Management Center\u2019s data access committee (email: sdac.data@fstrf.org) with the agreement of the IMPAACT Network. More information is available on\n                      \n                      and\n                      \n                      .","order":2,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics review board approvals for the IMPAACT P1026s study were received from the Colorado Multiple Institutional Review Board (CRV022-1), University of Southern California Institutional Review Board (HS-038044-CR019), Hospital Federal dos Servidores do Estado do Rio de Janeiro\/HFSE (CEP\u2014HFSE 2.359.725), Comit\u00e9 de \u00c9tica en Investigaci\u00f3n del Hospital General de Agudos \u201cDr. Jos\u00e9 Mar\u00eda Ramos Mej\u00eda\u201d, Rush Children's Hospital, Ethics Committee for the Development of Human Research Protections (IHRP) (GJ\/SP\/0363\/20), Ethics Committee of Chiangrai Prachanukhroh Hospital (GJ\/SP\/0099120), Uganda National Council for Science and Technology (HS 878) and Stellenbosch University Health Research Ethics Committee (N13\/02\/025_FAMCRU). This study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All pregnant participants provided written informed consent for themselves and their infants to take part in this study.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (data are presented in aggregate and no personally identifiable information has been included in this manuscript).","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MVS, TRC, DES, KG, RB, EVC, AMS, MM and BMB contributed to the conceptualization of the study and study design. KG, RB, EVC, AMS, MM and BMB contributed to the study implementation and oversight. MVS, TRC, GBT, MFC, DW, KR and LW contributed to the study implementation, data collection, and sample processing at the enrolling study sites and research laboratories. MVS, AB, EDC and ACE contributed to the literature search for the manuscript. KK and CS contributed to the data extraction. MVS, JW, AB, EDC, DES and BMB contributed to the data analysis. MVS, AB, EDC, and ACE contributed to the writing of the manuscript. All authors contributed to reviewing the manuscript, and all authors have read and approved the final version.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}